Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Details on Person Christensen, James G

Class:Id	Person:6800518
_displayName	Christensen, James G
_timestamp	2015-09-29 16:47:06
created	[InstanceEdit:6800517] Rothfels, Karen, 2015-09-29
firstname	James G
initial	JG
surname	Christensen
(author)	[LiteratureReference:6800629] A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells through [corrected] MAPK activation [LiteratureReference:8876008] Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752 [LiteratureReference:9674233] In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship [LiteratureReference:9701779] A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors [LiteratureReference:9710814] The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers [LiteratureReference:9713948] Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment [LiteratureReference:9736134] A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo [LiteratureReference:9736172] A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase [LiteratureReference:9736273] An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms [LiteratureReference:9736276] Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models List all 12 refering instances
[Change default viewing format]

No pathways have been reviewed or authored by Christensen, James G (6800518)